Αποτελέσματα Αναζήτησης
31 Ιαν 2022 · We evaluated the effects of antibiotic therapy on the clinical outcomes of COVID-19 pneumonia patients and diagnostic accuracy of key inflammatory markers to inform antibiotic decision-making. Methods: An observational cohort study was conducted in patients hospitalised with COVID-19 at the National Centre for Infectious Diseases and Tan Tock ...
1 Οκτ 2020 · An antibiotic treatment duration of five days in patients with COVID-19 and suspected bacterial respiratory infection is recommended upon improvement of signs, symptoms and inflammatory markers.
11 Αυγ 2023 · All but one of these recommendations apply to critically ill patients with COVID-19. A single guideline recommended “usual antimicrobial treatment” for pneumonia for all patients with COVID-19 (e.g., with and without radiographic abnormalities, in all levels of severity).
5 Ιαν 2021 · Results. We screened 7469 studies, from which 154 were included in the final analysis. Antibiotic data were available from 30 623 patients. The prevalence of antibiotic prescribing was 74.6% (95% CI 68.3–80.0%).
11 Νοε 2020 · Most bacterial pneumonias caught early enough can be safely and effectively treated with antibiotics, and broad-spectrum antibiotics are being widely used in patients with COVID-19. 8 However, antibiotic use drives the emergence of antibiotic-resistant bacteria.
Azithromycin (Zithromax) is the most consistently studied antibiotic for use in treating patients infected with the SARS-CoV-2 virus; it does not improve mortality after 28 days or affect the...
9 Σεπ 2021 · Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues 1 adds value to the current literature, and we would like to share our comments.
